REPORT ID 6990

Asia-Pacific Adalimumab Biosimilar Market Report 2017

Publish Date
1-Nov-17
Pages
119
Format
Electronic (PDF)

In this report, the Asia-Pacific Adalimumab Biosimilar market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Adalimumab Biosimilar for these regions, from 2012 to 2022 (forecast), including
    China
    Japan
    South Korea
    Taiwan
    India
    Southeast Asia
    Australia

Asia-Pacific Adalimumab Biosimilar market competition by top manufacturers/players, with Adalimumab Biosimilar sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    AET BioTech
    Amgen
    Boehringer Ingelheim
    Coherus Biosciences
    Fujifilm Kyowa Kirin Biologics
    LG Life Sciences/Mochida Pharmaceutical
    Momenta Pharmaceuticals
    Oncobiologics
    Pfizer
    Samsung Bioepsis
    Sandoz
    Zydus Cadila

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Tablet
    Oral Solution

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Adalimumab Biosimilar for each application, includin
    Hospital Pharmacy
    Retail Pharmacy
    Online Pharmacy

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Asia-Pacific Adalimumab Biosimilar Market Report 2017
1 Adalimumab Biosimilar Overview
    1.1 Product Overview and Scope of Adalimumab Biosimilar
    1.2 Classification of Adalimumab Biosimilar by Product Category
        1.2.1 Asia-Pacific Adalimumab Biosimilar Market Size (Sales) Comparison by Types (2012-2022)
        1.2.2 Asia-Pacific Adalimumab Biosimilar Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Tablet
        1.2.4 Oral Solution
    1.3 Asia-Pacific Adalimumab Biosimilar Market by Application/End Users
        1.3.1 Asia-Pacific Adalimumab Biosimilar Sales (Volume) and Market Share Comparison by Applications (2012-2022)
        1.3.2 Hospital Pharmacy
        1.3.3 Retail Pharmacy
        1.3.4 Online Pharmacy
    1.4 Asia-Pacific Adalimumab Biosimilar Market by Region
        1.4.1 Asia-Pacific Adalimumab Biosimilar Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 China Status and Prospect (2012-2022)
        1.4.3 Japan Status and Prospect (2012-2022)
        1.4.4 South Korea Status and Prospect (2012-2022)
        1.4.5 Taiwan Status and Prospect (2012-2022)
        1.4.6 India Status and Prospect (2012-2022)
        1.4.7 Southeast Asia Status and Prospect (2012-2022)
        1.4.8 Australia Status and Prospect (2012-2022)
    1.5 Asia-Pacific Market Size (Value and Volume) of Adalimumab Biosimilar (2012-2022)
        1.5.1 Asia-Pacific Adalimumab Biosimilar Sales and Growth Rate (2012-2022)
        1.5.2 Asia-Pacific Adalimumab Biosimilar Revenue and Growth Rate (2012-2022)

2 Asia-Pacific Adalimumab Biosimilar Competition by Players/Suppliers, Region, Type and Application
    2.1 Asia-Pacific Adalimumab Biosimilar Market Competition by Players/Suppliers
        2.1.1 Asia-Pacific Adalimumab Biosimilar Sales Volume and Market Share of Key Players/Suppliers (2012-2017)
        2.1.2 Asia-Pacific Adalimumab Biosimilar Revenue and Share by Players/Suppliers (2012-2017)
    2.2 Asia-Pacific Adalimumab Biosimilar (Volume and Value) by Type
        2.2.1 Asia-Pacific Adalimumab Biosimilar Sales and Market Share by Type (2012-2017)
        2.2.2 Asia-Pacific Adalimumab Biosimilar Revenue and Market Share by Type (2012-2017)
    2.3 Asia-Pacific Adalimumab Biosimilar (Volume) by Application
    2.4 Asia-Pacific Adalimumab Biosimilar (Volume and Value) by Region
        2.4.1 Asia-Pacific Adalimumab Biosimilar Sales and Market Share by Region (2012-2017)
        2.4.2 Asia-Pacific Adalimumab Biosimilar Revenue and Market Share by Region (2012-2017)

3 China Adalimumab Biosimilar (Volume, Value and Sales Price)
    3.1 China Adalimumab Biosimilar Sales and Value (2012-2017)
        3.1.1 China Adalimumab Biosimilar Sales Volume and Growth Rate (2012-2017)
        3.1.2 China Adalimumab Biosimilar Revenue and Growth Rate (2012-2017)
        3.1.3 China Adalimumab Biosimilar Sales Price Trend (2012-2017)
    3.2 China Adalimumab Biosimilar Sales Volume and Market Share by Type
    3.3 China Adalimumab Biosimilar Sales Volume and Market Share by Application

4 Japan Adalimumab Biosimilar (Volume, Value and Sales Price)
    4.1 Japan Adalimumab Biosimilar Sales and Value (2012-2017)
        4.1.1 Japan Adalimumab Biosimilar Sales Volume and Growth Rate (2012-2017)
        4.1.2 Japan Adalimumab Biosimilar Revenue and Growth Rate (2012-2017)
        4.1.3 Japan Adalimumab Biosimilar Sales Price Trend (2012-2017)
    4.2 Japan Adalimumab Biosimilar Sales Volume and Market Share by Type
    4.3 Japan Adalimumab Biosimilar Sales Volume and Market Share by Application

5 South Korea Adalimumab Biosimilar (Volume, Value and Sales Price)
    5.1 South Korea Adalimumab Biosimilar Sales and Value (2012-2017)
        5.1.1 South Korea Adalimumab Biosimilar Sales Volume and Growth Rate (2012-2017)
        5.1.2 South Korea Adalimumab Biosimilar Revenue and Growth Rate (2012-2017)
        5.1.3 South Korea Adalimumab Biosimilar Sales Price Trend (2012-2017)
    5.2 South Korea Adalimumab Biosimilar Sales Volume and Market Share by Type
    5.3 South Korea Adalimumab Biosimilar Sales Volume and Market Share by Application

6 Taiwan Adalimumab Biosimilar (Volume, Value and Sales Price)
    6.1 Taiwan Adalimumab Biosimilar Sales and Value (2012-2017)
        6.1.1 Taiwan Adalimumab Biosimilar Sales Volume and Growth Rate (2012-2017)
        6.1.2 Taiwan Adalimumab Biosimilar Revenue and Growth Rate (2012-2017)
        6.1.3 Taiwan Adalimumab Biosimilar Sales Price Trend (2012-2017)
    6.2 Taiwan Adalimumab Biosimilar Sales Volume and Market Share by Type
    6.3 Taiwan Adalimumab Biosimilar Sales Volume and Market Share by Application

7 India Adalimumab Biosimilar (Volume, Value and Sales Price)
    7.1 India Adalimumab Biosimilar Sales and Value (2012-2017)
        7.1.1 India Adalimumab Biosimilar Sales Volume and Growth Rate (2012-2017)
        7.1.2 India Adalimumab Biosimilar Revenue and Growth Rate (2012-2017)
        7.1.3 India Adalimumab Biosimilar Sales Price Trend (2012-2017)
    7.2 India Adalimumab Biosimilar Sales Volume and Market Share by Type
    7.3 India Adalimumab Biosimilar Sales Volume and Market Share by Application

8 Southeast Asia Adalimumab Biosimilar (Volume, Value and Sales Price)
    8.1 Southeast Asia Adalimumab Biosimilar Sales and Value (2012-2017)
        8.1.1 Southeast Asia Adalimumab Biosimilar Sales Volume and Growth Rate (2012-2017)
        8.1.2 Southeast Asia Adalimumab Biosimilar Revenue and Growth Rate (2012-2017)
        8.1.3 Southeast Asia Adalimumab Biosimilar Sales Price Trend (2012-2017)
    8.2 Southeast Asia Adalimumab Biosimilar Sales Volume and Market Share by Type
    8.3 Southeast Asia Adalimumab Biosimilar Sales Volume and Market Share by Application

9 Australia Adalimumab Biosimilar (Volume, Value and Sales Price)
    9.1 Australia Adalimumab Biosimilar Sales and Value (2012-2017)
        9.1.1 Australia Adalimumab Biosimilar Sales Volume and Growth Rate (2012-2017)
        9.1.2 Australia Adalimumab Biosimilar Revenue and Growth Rate (2012-2017)
        9.1.3 Australia Adalimumab Biosimilar Sales Price Trend (2012-2017)
    9.2 Australia Adalimumab Biosimilar Sales Volume and Market Share by Type
    9.3 Australia Adalimumab Biosimilar Sales Volume and Market Share by Application

10 Asia-Pacific Adalimumab Biosimilar Players/Suppliers Profiles and Sales Data
    10.1 AET BioTech
        10.1.1 Company Basic Information, Manufacturing Base and Competitors
        10.1.2 Adalimumab Biosimilar Product Category, Application and Specification
            10.1.2.1 Product A
            10.1.2.2 Product B
        10.1.3 AET BioTech Adalimumab Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
        10.1.4 Main Business/Business Overview
    10.2 Amgen
        10.2.1 Company Basic Information, Manufacturing Base and Competitors
        10.2.2 Adalimumab Biosimilar Product Category, Application and Specification
            10.2.2.1 Product A
            10.2.2.2 Product B
        10.2.3 Amgen Adalimumab Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
        10.2.4 Main Business/Business Overview
    10.3 Boehringer Ingelheim
        10.3.1 Company Basic Information, Manufacturing Base and Competitors
        10.3.2 Adalimumab Biosimilar Product Category, Application and Specification
            10.3.2.1 Product A
            10.3.2.2 Product B
        10.3.3 Boehringer Ingelheim Adalimumab Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
        10.3.4 Main Business/Business Overview
    10.4 Coherus Biosciences
        10.4.1 Company Basic Information, Manufacturing Base and Competitors
        10.4.2 Adalimumab Biosimilar Product Category, Application and Specification
            10.4.2.1 Product A
            10.4.2.2 Product B
        10.4.3 Coherus Biosciences Adalimumab Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
        10.4.4 Main Business/Business Overview
    10.5 Fujifilm Kyowa Kirin Biologics
        10.5.1 Company Basic Information, Manufacturing Base and Competitors
        10.5.2 Adalimumab Biosimilar Product Category, Application and Specification
            10.5.2.1 Product A
            10.5.2.2 Product B
        10.5.3 Fujifilm Kyowa Kirin Biologics Adalimumab Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
        10.5.4 Main Business/Business Overview
    10.6 LG Life Sciences/Mochida Pharmaceutical
        10.6.1 Company Basic Information, Manufacturing Base and Competitors
        10.6.2 Adalimumab Biosimilar Product Category, Application and Specification
            10.6.2.1 Product A
            10.6.2.2 Product B
        10.6.3 LG Life Sciences/Mochida Pharmaceutical Adalimumab Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
        10.6.4 Main Business/Business Overview
    10.7 Momenta Pharmaceuticals
        10.7.1 Company Basic Information, Manufacturing Base and Competitors
        10.7.2 Adalimumab Biosimilar Product Category, Application and Specification
            10.7.2.1 Product A
            10.7.2.2 Product B
        10.7.3 Momenta Pharmaceuticals Adalimumab Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
        10.7.4 Main Business/Business Overview
    10.8 Oncobiologics
        10.8.1 Company Basic Information, Manufacturing Base and Competitors
        10.8.2 Adalimumab Biosimilar Product Category, Application and Specification
            10.8.2.1 Product A
            10.8.2.2 Product B
        10.8.3 Oncobiologics Adalimumab Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
        10.8.4 Main Business/Business Overview
    10.9 Pfizer
        10.9.1 Company Basic Information, Manufacturing Base and Competitors
        10.9.2 Adalimumab Biosimilar Product Category, Application and Specification
            10.9.2.1 Product A
            10.9.2.2 Product B
        10.9.3 Pfizer Adalimumab Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
        10.9.4 Main Business/Business Overview
    10.10 Samsung Bioepsis
        10.10.1 Company Basic Information, Manufacturing Base and Competitors
        10.10.2 Adalimumab Biosimilar Product Category, Application and Specification
            10.10.2.1 Product A
            10.10.2.2 Product B
        10.10.3 Samsung Bioepsis Adalimumab Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
        10.10.4 Main Business/Business Overview
    10.11 Sandoz
    10.12 Zydus Cadila

11 Adalimumab Biosimilar Manufacturing Cost Analysis
    11.1 Adalimumab Biosimilar Key Raw Materials Analysis
        11.1.1 Key Raw Materials
        11.1.2 Price Trend of Key Raw Materials
        11.1.3 Key Suppliers of Raw Materials
        11.1.4 Market Concentration Rate of Raw Materials
    11.2 Proportion of Manufacturing Cost Structure
        11.2.1 Raw Materials
        11.2.2 Labor Cost
        11.2.3 Manufacturing Expenses
    11.3 Manufacturing Process Analysis of Adalimumab Biosimilar

12 Industrial Chain, Sourcing Strategy and Downstream Buyers
    12.1 Adalimumab Biosimilar Industrial Chain Analysis
    12.2 Upstream Raw Materials Sourcing
    12.3 Raw Materials Sources of Adalimumab Biosimilar Major Manufacturers in 2016
    12.4 Downstream Buyers

13 Marketing Strategy Analysis, Distributors/Traders
    13.1 Marketing Channel
        13.1.1 Direct Marketing
        13.1.2 Indirect Marketing
        13.1.3 Marketing Channel Development Trend
    13.2 Market Positioning
        13.2.1 Pricing Strategy
        13.2.2 Brand Strategy
        13.2.3 Target Client
    13.3 Distributors/Traders List

14 Market Effect Factors Analysis
    14.1 Technology Progress/Risk
        14.1.1 Substitutes Threat
        14.1.2 Technology Progress in Related Industry
    14.2 Consumer Needs/Customer Preference Change
    14.3 Economic/Political Environmental Change

15 Asia-Pacific Adalimumab Biosimilar Market Forecast (2017-2022)
    15.1 Asia-Pacific Adalimumab Biosimilar Sales Volume, Revenue and Price Forecast (2017-2022)
        15.1.1 Asia-Pacific Adalimumab Biosimilar Sales Volume and Growth Rate Forecast (2017-2022)
        15.1.2 Asia-Pacific Adalimumab Biosimilar Revenue and Growth Rate Forecast (2017-2022)
        15.1.3 Asia-Pacific Adalimumab Biosimilar Price and Trend Forecast (2017-2022)
    15.2 Asia-Pacific Adalimumab Biosimilar Sales Volume, Revenue and Growth Rate Forecast by Region (2017-2022)
        15.2.1 Asia-Pacific Adalimumab Biosimilar Sales Volume and Growth Rate Forecast by Region (2017-2022)
        15.2.2 Asia-Pacific Adalimumab Biosimilar Revenue and Growth Rate Forecast by Region (2017-2022)
        15.2.3 China Adalimumab Biosimilar Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.4 Japan Adalimumab Biosimilar Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.5 South Korea Adalimumab Biosimilar Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.6 Taiwan Adalimumab Biosimilar Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.7 India Adalimumab Biosimilar Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.8 Southeast Asia Adalimumab Biosimilar Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.9 Australia Adalimumab Biosimilar Sales, Revenue and Growth Rate Forecast (2017-2022)
    15.3 Asia-Pacific Adalimumab Biosimilar Sales, Revenue and Price Forecast by Type (2017-2022)
        15.3.1 Asia-Pacific Adalimumab Biosimilar Sales Forecast by Type (2017-2022)
        15.3.2 Asia-Pacific Adalimumab Biosimilar Revenue Forecast by Type (2017-2022)
        15.3.3 Asia-Pacific Adalimumab Biosimilar Price Forecast by Type (2017-2022)
    15.4 Asia-Pacific Adalimumab Biosimilar Sales Forecast by Application (2017-2022)

16 Research Findings and Conclusion

17 Appendix
    17.1 Methodology/Research Approach
        17.1.1 Research Programs/Design
        17.1.2 Market Size Estimation
        17.1.3 Market Breakdown and Data Triangulation
    17.2 Data Source
        17.2.1 Secondary Sources
        17.2.2 Primary Sources
    17.3 Disclaimer